Friday 16 October 2026
Export GLSI’s income statement to Excel — free account
Greenwich LifeSciences, Inc.
GLSI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.55
0.77
−5.03%
Follow GLSI
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 3.26 | 19.52 | 6.82 | 7.58 | 8.00 | 7.78 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 158.07 | 69.77 | 26.27 | 21.50 | 21.44 | 30.82 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 3 | 3 | 6 | 6 | 7 | 8 | 13 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | (2) | (2) | (3) | (2) | (5) | (8) | (9) | (17) | (19) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (2) | (3) | (2) | (5) | (8) | (9) | (17) | (19) | |||||
| Depreciation | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.13) | (0.14) | (1.52) | (0.20) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) | |||||
| Cash flow | — | (0.01) | (0.01) | (0.13) | (0.12) | (0.33) | (0.48) | (0.50) | (0.56) | (0.73) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.01) | (0.01) | (0.13) | (0.12) | (0.33) | (0.48) | (0.50) | (0.56) | (0.73) | |||||
| Book value | — | (0.73) | (0.86) | (0.60) | 2.91 | 2.07 | 1.02 | 0.52 | 0.07 | 0.03 | |||||
| Shares, m | — | 12 | 12 | 2 | 9 | 13 | 13 | 13 | 13 | 14 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | 0 | 0 | (1) | (4) | (6) | (6) | (7) | (10) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | 0 | 0 | 0 | (1) | (4) | (6) | (6) | (7) | (10) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | (1) | (1) | (1) | 28 | 27 | 13 | 7 | 1 | 0 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | 0 | 0 | 0 | (29) | (27) | (13) | (7) | (4) | (6) | |||||
| Shareholders’ equity | — | (9) | (10) | (1) | 28 | 27 | 13 | 7 | 1 | 0 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (2,320.80) | (3,114.65) | (5,067.01) | (12.98) | (16.35) | (38.46) | (86.87) | (314.09) | (376.92) | ||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 16.86 | 18.11 | 59.69 | (14.18) | (16.78) | (39.08) | (89.30) | (457.73) | (3,068.35) | |||||
Negative figures in brackets.
Charts ten years each
Greenwich LifeSciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio Inc. | $231.3M | 2.5× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| FATE Fate Therapeutics, Inc. | $230.7M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $224.9M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $224.9M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | |
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 10.9× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | Compare |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $222.5M | — | — | −43.70% | — | +1.75% | 100.00% | 0.00% |
Greenwich LifeSciences, Inc. (GLSI) key facts
- Greenwich LifeSciences, Inc. (GLSI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, GLSI traded at $14.55, a market capitalization of $224.9 million.
- Return on equity was −3,068.4% and debt-to-equity 0.00.
Greenwich LifeSciences, Inc. (GLSI) Latest News
No news at this impact. Lower the threshold for more.